Obesity Market Size is projected to grow rapidly with a significant CAGR by 2034

In 2023, the United States held the largest market share for obesity, exceeding USD 2,000 million. This surpassed the market sizes of obesity in comparison to the 7MM countries, the Obesity market size is anticipated to grow with a significant CAGR during the study period (2020-2034). DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Obesity landscape.

DelveInsight estimates that in 2023, the United States accounted for roughly 60% of the total adult obesity cases across the 7MM. Obesity prevalence among US adults has been on an upward trend. According to DelveInsight, the highest number of obesity cases in 2023 was observed in adults over 19 years as well as in children aged 5–19 years. These figures are expected to rise in both age groups at a moderate CAGR.

According to DelveInsight, the United States represented around 60% of the total adult obesity cases across the 7 major markets (7MM) in 2023. In recent years, there has been an increasing emphasis on developing innovative obesity treatments, including combination therapies such as SAXENDA (liraglutide), XENICAL (orlistat), WEGOVY (semaglutide), QYSMIA (phentermine-topiramate), and others.

The dynamics of the obesity market are expected to evolve as companies worldwide actively focus on developing new drug therapies to address obesity and overweight conditions. Leading players, including Novo Nordisk, Eli Lilly, Boehringer Ingelheim, and others, are working on innovative treatments aimed at managing overweight and obesity, ultimately supporting effective weight management.

DelveInsight’s report, “Obesity Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the obesity landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. 

Additionally, it examines Obesity market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Obesity market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Obesity Market Forecast

Some of the key facts of the Obesity Market Report:

• By the year 2034, it is expected that WEGOVY (Semaglutide) and ZEPBOUND (Tirzepatide) will attain significant market dominance across the seven major markets.
• Key Obesity Companies: Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others
• Key Obesity Therapies: IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others
• The Obesity market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Obesity pipeline products will significantly revolutionize the Obesity market dynamics.

Obesity Overview

Obesity is a chronic health condition characterized by excessive accumulation of body fat that negatively affects overall health. It is commonly defined using Body Mass Index (BMI), where a BMI of 30 or higher indicates obesity. The condition results from an imbalance between calorie intake and energy expenditure, influenced by genetic, environmental, behavioral, and metabolic factors.
Obesity increases the risk of serious health problems such as type 2 diabetes, heart disease, high blood pressure, stroke, certain cancers, and joint disorders. Management typically involves lifestyle modifications such as healthy eating and physical activity, along with medical or surgical interventions for severe cases. Early prevention and long-term weight management are crucial for reducing associated health risks.

Get a Free sample for the Obesity Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market

Key Trends in Obesity Therapeutics Market: 

• Shift Toward Novel Incretin-Based Therapies: Rapid adoption of GLP-1, GIP/GLP-1, and dual/triple agonist drugs (e.g., semaglutide, tirzepatide) is reshaping the treatment landscape with superior weight-loss efficacy compared to traditional therapies.
• Expanding Indications Beyond Weight Management: Obesity medicines are increasingly being evaluated for associated conditions such as Type 2 diabetes, cardiovascular disease, sleep apnea, and nonalcoholic steatohepatitis (NASH), broadening clinical and commercial potential.
• Rising Demand Driven by Increasing Disease Awareness and Diagnosis Rates: Growing recognition of obesity as a chronic metabolic disease rather than a lifestyle issue is improving diagnosis, treatment uptake, and payer acceptance.
• Surge in Biopharma R&D Investment and Robust Pipeline Growth: Numerous companies are advancing next-generation injectables, oral formulations, and long-acting biologics to improve patient convenience and adherence.
• Growing Focus on Combination Therapies and Precision Medicine: Research is exploring synergistic multi-target agents and patient-specific treatment strategies based on genetics, gut-hormone signaling, and metabolic profiles.

Obesity Epidemiology

The Obesity epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Obesity Epidemiology Segmentation:

The Obesity market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of Obesity in the 7MM
• Total Obesity Patients Seeking Help in the 7MM
• Total Treated Cases of Obesity in the 7MM

Download the report to understand which factors are driving Obesity epidemiology trends @ Obesity Epidemiology Forecast

Recent Development In The Obesity Treatment Landscape:

• In May 2025, ICON plc (NASDAQ: ICLR), a global leader in clinical research driven by healthcare intelligence, has published the results of a survey involving 155 biotech and pharmaceutical professionals from the US and Europe. The survey focused on multi-indication cardiometabolic research and development (R&D) for therapies targeting obesity and its related conditions. Multi-indication studies refer to clinical trials that evaluate the effectiveness of a treatment across multiple diseases or conditions.
• In April 2025, Corxel Pharmaceuticals has obtained clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application, allowing the initiation of a randomized Phase II trial in the US for CX11, an oral small molecule GLP-1 receptor agonist (GLP-1 RA) aimed at treating obesity. This double-blind, placebo-controlled study will evaluate the safety and effectiveness of the once-daily therapy in individuals who are overweight or obese. Corxel plans to begin enrolling participants in the second quarter of this year, with topline results anticipated in the first half of 2026.
• In March 2025, Zealand Pharma completed enrollment for its global, randomized Phase IIb ZUPREME-1 trial, which is evaluating petrelintide, a long-acting amylin analogue, in people with obesity or overweight and associated comorbidities. This placebo-controlled, multi-center, parallel-group study aims to compare the once-weekly subcutaneous injection of petrelintide to a placebo in terms of safety, tolerability, and impact on body weight.
• In January 2025, Novo Nordisk’s high-dose formulation of Wegovy (semaglutide) has demonstrated enhanced weight loss benefits while maintaining a favorable safety and tolerability profile. In the Phase IIIb STEP UP trial, the 7.2mg dose of Wegovy showed statistically significant and superior weight reduction at week 72. The study involved 1,407 adults with obesity who were randomized to receive once-weekly injections alongside lifestyle modification support.
• In January 2025, Viking Therapeutics has initiated a Phase II clinical trial for VK2735, an oral tablet developed to address metabolic conditions like obesity. The VENTURE-Oral Dosing Trial is a randomized, double-blind, placebo-controlled, multi-center study designed to evaluate the safety, tolerability, and effectiveness of the drug in promoting weight loss over a 13-week period.
• In July 2024, Roche announced promising topline results from its ongoing multi-part Phase I clinical trial of CT-996, an oral GLP-1 receptor agonist intended for the treatment of type 2 diabetes (T2D) and obesity. Known as the CT-996-201 trial, this comprehensive, multi-cohort, double-blind, randomized, placebo-controlled study includes both single and multiple ascending dose arms, with two arms already completed. The trial aims to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of CT-996 in overweight or obese adults, regardless of their T2D status.

Obesity Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Obesity market or expected to get launched during the study period. The analysis covers Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Obesity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Obesity Therapies and Key Companies

• IMCIVREE (setmelanotide): Rhythm Pharmaceuticals
• ZEPBOUND (tirzepatide): Eli Lilly and Company
• Survodutide (BI 456906): Boehringer Ingelhium
• DD03: D&D Pharmatech
• AX-0601: ProQR Therapeutics
• NPM 139: Nano Precision Medical
• BK-1701: Bukwang Pharmaceutical
• CBW-520: Caliway Biopharmaceutics
• YH34160: Yuhan
• TERN-601: Terns Pharmaceuticals
• Thermostem: BioRestorative Therapies
• SCO-267: SCOHIA PHARMA
• CT-181: Click Therapeutics
• HM15136: Hanmi Pharmaceuticals
• NNC0480-0389: Novo Nordisk
• EMP-16: Empros Pharma
• CT-868: Carmot Therapeutics
• Tirzepatide: Eli Lilly and Company
• Semaglutide Oral: Novo Nordisk

Discover more about therapies set to grab major Obesity market share @ Obesity Treatment Landscape

Obesity Market Drivers

• Rising global prevalence of obesity, fueled by sedentary lifestyles, unhealthy diets, and urbanization.
• Increasing awareness of obesity-related comorbidities, such as diabetes, cardiovascular diseases, and hypertension.
• Advancements in obesity management therapies, including pharmacological treatments, medical devices, and bariatric surgery.
• Growing healthcare initiatives and government programs promoting weight management and prevention.
• Rising demand for personalized and non-invasive treatment options, supporting market growth.

Obesity Market Barriers

• High cost of advanced therapies and surgical interventions, limiting patient accessibility.
• Patient non-adherence to lifestyle modifications and long-term treatment plans, reducing effectiveness.
• Social stigma and psychological barriers, affecting diagnosis and treatment-seeking behavior.
• Variability in patient response to treatments, complicating therapy standardization.
• Limited awareness in developing regions, leading to underdiagnosis and insufficient management.

Scope of the Obesity Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Obesity Companies: Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others
• Key Obesity Therapies: IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others
• Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies
• Obesity Market Dynamics: Obesity market drivers and Obesity market barriers
• Obesity Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Obesity Unmet Needs, KOL’s views, Analyst’s views, Obesity Market Access and Reimbursement 

To know more about Obesity companies working in the treatment market, visit @ Obesity Clinical Trials and Therapeutic Assessment

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.